Abciximab

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident, Brain Ischemia, Acute Disease

Trial Timeline

Oct 1, 2003 → Dec 1, 2005

NCT ID

NCT00073372

About Abciximab

Abciximab is a phase 3 stage product being developed by Eli Lilly for Cerebrovascular Accident. The current trial status is terminated. This product is registered under clinical trial identifier NCT00073372. Target conditions include Cerebrovascular Accident, Brain Ischemia, Acute Disease.

What happened to similar drugs?

5 of 6 similar drugs in Cerebrovascular Accident were approved

Approved (5) Terminated (0) Active (1)

🔄donepezil hclEisaiPhase 3

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved

✅AtorvastatinPfizerApproved

✅Botulinum toxin type A + PlaceboIpsenApproved

✅Atorvastatin 20mgBrain BiotechApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00178451	Phase 1/2	Withdrawn	—	—	Carotid Stenosis
NCT00440895	Approved	Completed	Feb 1, 2007	May 1, 2013	Myocardial Infarction
NCT00440778	Approved	Completed	Feb 1, 2007	Oct 1, 2008	Myocardial Infarction
NCT00420030	Approved	Completed	Sep 1, 2006	Jun 1, 2009	Shock, Cardiogenic
NCT00354406	Approved	Completed	Apr 1, 2006	Dec 1, 2008	Myocardial Infarction
NCT00167765	Phase 3	Terminated	Mar 1, 2005	May 1, 2005	Stroke
NCT00126139	Phase 3	Terminated	Apr 1, 2004	May 1, 2005	Stroke
NCT00073372	Phase 3	Terminated	Oct 1, 2003	Dec 1, 2005	Cerebrovascular Accident
NCT00169819	Approved	Completed	Oct 1, 2003	Apr 1, 2006	Coronary Artery Disease

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors

Product	Company	Stage	Hype Score
YM872 (zonampanel)	Astellas Pharma	Phase 2	35
donepezil hcl	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43
ONO-2506	Ono Pharmaceutical	Phase 2/3	30
atomoxetine + Stimulants	Eli Lilly	Pre-clinical	26
ticagrelor + ASA + Placebo+ASA	AstraZeneca	Approved	43
Valsartan	Novartis	Pre-clinical	18
Atorvastatin	Pfizer	Approved	43
Rivaroxaban	Bayer	Pre-clinical	19
Darolutamide (BAY1841788) + Enzalutamide	Bayer	Phase 1	26
Botulinum toxin type A + Placebo	Ipsen	Approved	40
Atorvastatin 20mg	Brain Biotech	Approved	40
Autologous bone marrow mononuclear cell transplantation	Brain Biotech	Phase 1	11
Roflumilast Oral Tablet	Brain Biotech	Phase 2	25